Soligenix (SNGX) EBT (2010 - 2026)
Soligenix's (SNGX) quarterly EBT came in at -$2.9 million in Q1 2026, up 10.87% YoY from -$2.6 million in Q1 2025, and up 16.97% on a QoQ basis from -$3.5 million in Q4 2025.
Soligenix (SNGX) EBT (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of EBT data on file, last reported at -$2.9 million in Q1 2026.
- Quarterly EBT rose 10.87% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.7 million (down 17.07% YoY) and the FY2025 annual result came in at -$11.6 million, down 33.56% from the prior year.
- EBT improved to -$2.9 million in Q1 2026, from -$3.5 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$1.6 million in Q2 2023 to a low of -$4.3 million in Q1 2022.
- A 5-year average of -$2.7 million and a median of -$2.8 million in 2025 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT plunged 84.09% — and 2023, when it jumped 54.48%.
- Tracing SNGX's EBT over 5 years: stood at -$3.8 million in 2022, then soared by 35.35% to -$2.4 million in 2023, then sank by 39.97% to -$3.4 million in 2024, then declined by 2.3% to -$3.5 million in 2025, then gained by 16.97% to -$2.9 million in 2026.
- The last three EBT figures came in at -$2.9 million (Q1 2026), -$3.5 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 81.49 Mn |
| 10 | Soligenix | 6.08 Mn | 6.08 Mn | - | -2.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.10 Mn |
| Mar 31, 2026 | -2.88 Mn |
| Dec 31, 2025 | -3.47 Mn |
| Sep 30, 2025 | -2.58 Mn |
| Jun 30, 2025 | -2.76 Mn |
| Mar 31, 2025 | -3.24 Mn |
| Dec 31, 2024 | -3.40 Mn |
| Sep 30, 2024 | -1.72 Mn |
| Jun 30, 2024 | -1.64 Mn |
| Mar 31, 2024 | -1.92 Mn |
| Dec 31, 2023 | -2.43 Mn |
| Sep 30, 2023 | -1.66 Mn |
| Jun 30, 2023 | -1.61 Mn |
| Mar 31, 2023 | -2.21 Mn |
| Dec 31, 2022 | -3.75 Mn |
| Sep 30, 2022 | -3.31 Mn |
| Jun 30, 2022 | -3.54 Mn |
| Mar 31, 2022 | -4.35 Mn |
| Dec 31, 2021 | -4.70 Mn |
| Sep 30, 2021 | -3.59 Mn |